^
    over1year
    Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors. (PubMed, Cell Death Dis)
    Ectopic overexpression of Btg2 inhibited the EMT response, blocking cell migration, and promoted cancer cell death. These data demonstrate that the combination therapy of T1-44 with Vactosertib is synergistic for pancreatic cancer, suggesting that this novel combination therapy has value in the treatment strategy of patients with pancreatic cancer.
    Preclinical • Journal
    |
    PRMT5 (Protein Arginine Methyltransferase 5) • TGFB1 (Transforming Growth Factor Beta 1) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    vactosertib (TEW-7197) • AT101